Inherited pancreatic cancer syndromes

Cancer Journal (United States)

Volumn 18, Issue 6, 2012, Pages 485-491

  Solomon, Sheila ^a   Das, Siddhartha ^a   Brand, Randall ^a   Whitcomb, David C ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

APC; ATM; BRCA1; BRCA2; CDKN2A; Familial pancreatic cancer; genetic counseling; genetics; MLH1; MSH2; MSH6; PALB2; PMS2; PRSS1; risk reduction therapy and medical management of pancreatic cancer risk; STK11

Indexed keywords

APC PROTEIN; ATM PROTEIN; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN; PROTEIN SERINE THREONINE KINASE; PRSS1 PROTEIN; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ATAXIA TELANGIECTASIA; CANCER EPIDEMIOLOGY; COLORECTAL CANCER; DNA REPAIR; FAMILIAL CANCER; FAMILY; FANCONI ANEMIA; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HIGH RISK PATIENT; HUMAN; INHERITANCE; PANCREAS CANCER; PANCREATITIS; PEUTZ JEGHERS SYNDROME; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; CARCINOMA, PANCREATIC DUCTAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; PANCREATIC NEOPLASMS;

EID: 84871211933     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318278c4a6     Document Type: Review

References (70)

1. Lewis ZK, Frost CJ, Venne VL. Pancreatic cancer surveillance among high-risk populations: knowledge and intent. J Genet Couns. 2009;18: 229-238.
2. Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: state-of-the-art care. CA Cancer J Clin. 2000;50:241-268.
3. Brand RE, Lerch MM, Rubinstein WS, et al. Advances in counselling and surveillance of patients at risk for pancreatic cancer. Gut. 2007; 56:1460-1469.
4. Klein AP, Beaty TH, Bailey-Wilson JE, et al. Evidence for a major geneinfluencing risk of pancreatic cancer. Genet Epidemiol. 2002;23: 133-149.
5. Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst. 1998;90: 1039-1071.
6. Brune KA, Lau B, Palmisano E, et al. Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010;102:119-126.
7. Brand RE, Greer JB, Zolotarevsky E, et al. Pancreatic cancer patients who smoke and drink are diagnosed at younger ages. Clin Gastroen-terol Hepatol. 2009;7:1007-1012.
8. Canto MI, Hruban RH, Fishman EK, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterol. 2012;142:796-804; quiz e714-e795.
9. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 pene-trance. J Clin Oncol. 2007;25:1329-1333.
10. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77:2318-2324.
11. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807-2816.
12. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
13. Struewing JP, Hartge P, Wacholder S, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401-1408.
14. Brose MS, Rebbeck TR, Calzone KA, et al. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst. 2002;94:1365-1372.
15. Beger C, Ramadani M, Meyer S, et al. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. Clin Cancer Res. 2004;10:3780-3787.
16. Moran A, O'Hara C, Khan S, et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Fam Cancer. 2012;11:235-242.
17. Axilbund JE, Argani P, Kamiyama M, et al. Absence of germline BR-CA1 mutations in familial pancreatic cancer patients. Cancer Biol Ther. 2009;8:131-135.
18. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-792.
19. Sharan SK, Morimatsu M, Albrecht U, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature. 1997;386:804-810.
20. Goggins M, Schutte M, Lu J, et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360-5364.
21. Murphy KM, Brune KA, Griffin C, et al. Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. Cancer Res. 2002;62: 3789-3793.
22. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310-1316.
23. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913-917.
24. Fogelman DR, Wolff RA, Kopetz S, et al. Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 2011;31:1417-1420.
25. Feldmann G, Karikari C, dal Molin M, et al. Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adeno-carcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther. 2011;11:959-968.
26. Rahman N, Seal S, Thompson D, et al. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet. 2007;39:165-167.
27. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324:217.
28. Casadei S, Norquist BM, Walsh T, et al. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71:2222-2229.
29. Geoffroy-Perez B, Janin N, Ossian K, et al. Cancer risk in heterozygotes for ataxia-telangiectasia. Int J Cancer. 2001;93:288-293.
30. Sahu RP, Batra S, Srivastava SK. Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 2009;100:1425-1433.
31. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Disc. 2012;2:41-46.
32. Gatti R. Ataxia-telangiectasia. In: Pagon RA, Bird TD, Dolan CR, et al, eds. Gene Rev. 1993; updated 2010 Mar11.
33. Kanda M, Matthaei H, Wu J, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology. 2012;142:730-733, e739.
34. Vasen HF, Gruis NA, Frants RR, et al. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87:809-811.
35. McWilliams RR, Wieben ED, Rabe KG, et al. Prevalence of CDKN2A mutations in pancreatic cancer patients: implications for genetic counseling. Eur J Hum Genet. 2011;19:472-478.
36. Petersen GM, Slack J, Nakamura Y. Screening guidelines and premor-bid diagnosis of familial adenomatous polyposis using linkage. Gastro-enterology. 1991;100:1658-1664.
37. Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli: a review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis. 2001;16:63-75.
38. Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology. 2001;121:198-213.
39. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations. Clin Genet. 2009;75:141-149.
40. Kastrinos F, Mukherjee B, Tayob N, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302:1790-1795.
41. Geary J, Sasieni P, Houlston R, et al. Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). Fam Cancer. 2008;7:163-172.
42. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14:141-145.
43. Amann ST, Gates LK, Aston CE, et al. Expression and penetrance of the hereditary pancreatitis phenotype in monozygotic twins. Gut. 2001;48:542-547.
44. Rebours V, Levy P, Ruszniewski P. An overview of hereditary pancreatitis. Dig Liver Dis. 2011;44:8-15.
45. Whitcomb DC. Genetic aspects of pancreatitis. 2010;61:413-424.
46. Lowenfels AB, Maisonneuve P, Whitcomb DC, et al. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286:169-170.
47. Rebours V, Boutron-Ruault MC, Jooste V, et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uni-and multidimensional analyses. Dig Liver Dis. 2009;104:2312-2317.
48. Rhim AD, Mirek ET, Aiello NM, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148:349-361.
49. Daniluk J, Liu Y, Deng D, et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 2012;122:1519-1528.
50. Ulrich CD II. Pancreatic cancer in hereditary pancreatitisYconsensus guidelines for prevention, screening, and treatment. Pancreatology. 2001;1:416-422.
51. Sutton JM, Schmulewitz N, Sussman JJ, et al. Total pancreatectomy and islet cell autotransplantation as a means of treating patients with genetically linked pancreatitis. Surgery. 2010;148:676-685; discussion 685-676.
52. Giardiello FM, Brensinger JD, Tersmette AC, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119: 1447-1453.
53. Maheu C, Vodermaier A, Rothenmund H, et al. Pancreatic cancer risk counselling and screening: impact on perceived risk and psychological functioning. Familial Cancer. 2010;9:617-624.
54. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res. 2004;64: 2634-2638.
55. Ghiorzo P, Pensotti V, Fornarini G, et al. Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy. Fa-milial Cancer. 2012;11:41-47.
56. Stadler ZK, Salo-Mullen E, Patil SM, et al. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer. 2012;118:493-499.
57. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009;27:433-438.
58. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Instit. 2003;95:214-221.
59. Ghiorzo P, Fornarini G, Sciallero S, et al. CDKN2A is the main susceptibility gene in Italian pancreatic cancer families. J Med Genet. 2012;49:164-170.
60. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. Ann Surg. 2002;236:730-737.
61. Moore PS, Missiaglia E, Antonello D, et al. Role of disease-causing genes in sporadic pancreatic endocrine tumors: MEN1 and VHL. Genes Chrom Cancer. 2001;32:177-181.
62. Park JH, Kim IJ, Kang HC, et al. Germline mutations of the MEN1 gene in Korean families with multiple endocrine neoplasia type 1 (MEN1) or MEN1-related disorders. Clin Genet. 2003;64:48-53.
63. Ohye H, Sato M, Matsubara S, et al. A novel germline mutation of multiple endocrine neoplasia type 1 (MEN1) gene in a Japanese MEN1 patient and her daughter. Endocrine J. 1999;46:325-329.
64. Bartsch D, Kopp I, Bergenfelz A, et al. MEN1 gene mutations in 12 MEN1 families and their associated tumors. Eur J Endocrinol. 1998; 139:416-420.
65. Gargiulo S, Torrini M, Ollila S, et al. Germline MLH1 and MSH2 mutations in Italian pancreatic cancer patients with suspected Lynch syndrome. Familial Cancer. 2009;8:547-553.
66. Lindor NM, Petersen GM, Spurdle AB, et al. Pancreatic cancer and a novel MSH2 germline alteration. Pancreas. 2011;40:1138-1140.
67. Banville N, Geraghty R, Fox E, et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol. 2006; 37:1498-1502.
68. Slater EP, Langer P, Niemczyk E, et al. PALB2 mutations in European familial pancreatic cancer families. Clin Genet. 2010;78:490-494.
69. Tischkowitz MD, Sabbaghian N, Hamel N, et al. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer. Gastroenterology. 2009;137:1183-1186.
70. Gorry MC, Gabbaizedeh D, Furey W, et al. Mutations in the cationic trypsinogen gene are associated with recurrent acute and chronic pancreatitis. Gastroenterology. 1997;113:1063-1068.